International Stem Cell Corporation Announces Publication of Preclinical Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
CARLSBAD, CA-(Marketwired — June 02, 2016) — International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of a 12-month pre-clinical, non-human primate study.